Corrigendum to "Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis" [Heliyon Volume 8, Issue 8, August 2022, Article e09773].

[This corrects the article DOI: 10.1016/j.heliyon.

Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF), a disorder observed mostly in older human beings, is characterised by chronic and progressive lung scarring leading to an irreversible decline in lung function. This health condition has a dismal prognosis and the currently available drugs only delay but fail to reverse the progression of lung damage. Consequently, it becomes imperative to discover improved therapeutic compounds and their cellular targets to cure IPF.